67 reports

Of these, the majority of operations are in the area of obstetrics and gynecology, digestive/ gastrointestinal tract CONCLUSIONS Conclusion ## Chapter One: Executive Summary ## procedures, and orthopedics.

  • Health Services
  • Hospital
  • Obesity
  • World
  • Forecast
  • HUMAN MICROBIOME MARKET: MARKET SHARE, BY DISEASE, GLOBAL, 2025
  • HUMAN MICROBIOME MARKET: REVENUE IN USD MILLION, BRAZIL, BY DISEASE, 2018-2025

The global human microbiome market is expected to account for nearly USD 273.40 million, registering a CAGR of about 22.6% during 2018-2025 (the forecast period). Moreover, the market is expected to reach USD 757.26 million by 2025. Increasing Incidence of Lifestyle Diseases The rising incidence of lifestyle diseases at the global...

  • Obesity
  • United States
  • DuPont
  • Enterome Bioscience SA
  • Synlogic, Inc.

Ingenious marketing and branding efforts have transformed this niche segment into one of the fastest growing one.

  • Health Beverage
  • Obesity
  • World
  • Market Size
  • Britvic plc

SOCIETY OF AMERICAN GASTROINTESTINAL AND ENDOSCOPIC SURGEONS (SAGES) (2015).

  • Hospital
  • Obesity
  • World
  • Ethicon, Inc.
  • Medtronic, Inc.
  • 7.5 NON-INVASIVE BARIATRIC SURGERY
  • 5.2 MARKET DYNAMICS

ONE OF THE MAJOR CONTRIBUTING FACTORS TO THE FIRM' S REVENUE GROWTH WAS THE INCREASING NUMBER OF SURGICAL PROCEDURES IN JAPAN, CHINA, AND SOUTH KOREA. ## ##. ##. ## M N M V I E W ## ##. ##. ## APOLLO ENDOSURGERY O V E R V I E W ## ##. ## FOUNDED IN 2005 AND

  • Obesity
  • North America
  • United States
  • Ethicon, Inc.
  • Medtronic, Inc.

For instance, in February 2017, Johnson & Johnson' s Ethicon announced the acquisition of Torax Medical, which helps in strengthening the product line for gastrointestinal problems.

  • Medical Tourism
  • Obesity
  • United States
  • Forecast
  • Medtronic, Inc.

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Obesity
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • CHAPTER IV ANTI-OBESITY DRUGS PRODUCTION AND DEMAND
  • CHAPTER IV ANTI-OBESITY DRUGS PRODUCTION AND DEMAND

The auto exports exceeded over ## million each year.

  • Obesity
  • Pathology
  • China
  • Demand
  • Abbott Laboratories, Inc.
  • Nu clear receptor, 1, 3%
  • DIABETES AND OBESITY THERAPEUTICS MARKET, GLOBAL, REVENUE FORECAST FOR ERTUGLIFLOZIN

One-year treatment of obesity: a randomized, double-blind, placebocontrolled, multicenter study of orlistat, a gastrointestinal lipase inhibitor.

  • Obesity
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group

Obesity Drugs and Therapies: Technologies and Global Markets OBESITY DRUGS AND THERAPIES: TECHNOLOGIES AND GLOBAL MARKETS CHAPTER ## INTRODUCTION ## STUDY GOAL AND OBJECTIVES ## SCOPE OF REPORT ## INTENDED AUDIENCE ## METHODOLOGY ## INFORMATION SOURCES ## ANALYST' S CREDENTIALS ## RELATED BCC R

  • Obesity
  • Pathology
  • Pharmaceutical
  • Therapy
  • World
  • CHAPTER IV ANTI-OBESITY DRUGS PRODUCTION AND DEMAND

This is Herbalife' s one and only manufacturing base apart from the one in America.

  • Obesity
  • China
  • Demand
  • Abbott Laboratories, Inc.
  • Shanghai Jahwa United Co., Ltd.

You can easily book an appointment with one online.

  • Obesity
  • Allergan plc
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

This is Herbalife' s one and only manufacturing base apart from the one in America.

  • Obesity
  • China
  • Abbott Laboratories, Inc.
  • Beijing Outsell Health Product Development Co., Ltd.
  • Shanghai Jahwa United Co., Ltd.

The auto exports exceeded over ## million each year.

  • Diagnostic Reagent
  • China
  • Demand
  • Market Size
  • Biosino Bio-Technology & Science Inc

However, the need for frequent dosing and the drug' s gastrointestinal side effects are a challenge in terms of patient adherence.

  • Obesity
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Novo Nordisk Group
  • VIVUS, Inc.
  • A 20-minutes procedure
  • Key Vendor Analysis

More than ## in ## men and ## in ## women are overweight in the country.

  • Obesity
  • United States
  • Apollo Endosurgery, Inc.
  • Hélioscopie SA
  • Obalon Therapeutics, Inc.

This procedure does not alter the gastrointestinal anatomy.

  • Obesity
  • Pathology
  • United States
  • World
  • Forecast

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

It absorbs the water in the gastrointestinal tract, thereby producing a feeling fullness for a longer time and helping in weight loss.

  • Obesity
  • Canada
  • Forecast
  • AMER SPORTS CANADA INC.
  • Kellogg Canada Inc.

Pancreatic cancer

4546 5000 3864
  • STRENGTHS AND LIMITATIONS

Journal of Gastrointestinal Cancer, ##, ##-## < DOI> ##. ##/ s##-##-##-##< / DOI>.

  • Obesity
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • CONTINUED)
  • 5. OTHER EMERGING MEDICAL DEVICE TECHNOLOGIES ....................... 5-1

According to National Health and Nutrition Examination Survey (NHANES), approximately 35%, or nearly one out of three adults age 20 years or older were classified as obese in 2012 (the latest available statistics) based on a BMI of 30 kg/m2 or greater. This translates to more than 100 million obese people in the U.S.—a staggering number. Obesity...

  • Obesity
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.
  • 09. Market Segmentation by Drug Class
  • 16. Market Trends

It includes orlistat, a reversible inhibitor of gastrointestinal lipases.

  • Obesity
  • United States
  • Arena Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES; ##(##): ##-##.

  • Obesity
  • United States
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.

GASTROINTESTINAL (GI) DISORDERS ##. ##. ##.

  • Obesity
  • United States
  • Enterome Bioscience SA
  • MicroBiome Therapeutics LLC
  • Seres Therapeutics, Inc.

This is an advantage as oral antiplatelet therapy can lead to gastrointestinal adverse events.

  • Obesity
  • United States
  • AstraZeneca PLC
  • NSTEMI group
  • The Medicines Company
  • MAY 11, 2017: ZEALAND PHARMA DISCLOSES AMYLIN AS THE BIOLOGICAL TARGET UNDER THEIR 2014 AGREEMENT WITH BOEHRINGER INGELHEIM

That number increases to one in three at age ##.

  • Insulin
  • Obesity
  • World
  • Product Initiative
  • Amylin Pharmaceuticals, Inc.
  • GELESIS100 PEDIATRIC AND OBESE OVERWEIGHT - PRODUCT DESCRIPTION
  • GELESIS100 PREDIABETIC AND DIABETIC OVERWEIGHT - PRODUCT DESCRIPTION

One unit refers to one gastric band.

  • Clinical Trial
  • Hospital
  • Medical Device
  • Obesity
  • GlobalData's company

The drug candidate is an agonist of TGR##, a G protein-coupled receptor found in the gastrointestinal (GI) tract.

  • Obesity
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

His clinical areas of expertise include laparoscopic and gastrointestinal surgery.

  • Hospital
  • Obesity
  • United States
  • Company
  • GI Dynamics